This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.
At the American Society of Nephrology’s Kidney Week 2011, Fresenius Medical Care (NYSE: FMS), the world’s largest provider of dialysis products and services, announced that it received U.S. Food and Drug Administration 510 (K) clearance to extend improved touch screen navigation on its most advanced hemodialysis delivery system, the 2008T. Effective immediately, all newly produced 2008T machines with Fresenius Clinical Data Exchange (CDX) will come with this enhancement. Introduced a year ago at Kidney Week 2010, the 2008T is the first fully integrated therapy and management information system on the market. The 2008T combines Fresenius Medical Care’s most advanced hemodialysis delivery system with CDX providing caregivers, for the first time, chair-side access to the facility’s medical information system and dialysis treatment data. “With all the key information a medical professional needs, immediately at hand, they can focus on patient care. The human factors engineering is an appreciation of how medical professionals actually work in the clinical setting. The 2008T puts key patient and treatment information more quickly at the clinicians’ fingertips,” said Jose A. Diaz-Buxo, MD, FACP, Chief Medical & Regulatory Affairs Officer, Fresenius Medical Care. “Simplicity, ease of use and readily available information allows care-givers more time to focus on the patient.” About Fresenius Medical Care Fresenius Medical Care (NYSE: FMS) is the world’s leading company devoted to patient-oriented renal therapy. Through more than 2,900 clinics in North America, Europe, Latin America, Asia-Pacific and Africa, we provide kidney dialysis treatments to approximately 228,000 patients worldwide. We are also the world's leading maker of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Chronic kidney failure is a condition that affects about 2 million individuals worldwide. For more information about the company’s more than 1,800 U.S. dialysis facilities, visit www.ultracare-dialysis.com (in English and Spanish). For more information about Fresenius Medical Care, visit www.fmc-ag.com or www.fmcna.com Legal Disclaimer: